上海市高血壓研究所于1958年成立，是一所集流行病學(xué)、臨床診治、發(fā)病機(jī)制和社區(qū)防治研究為一體的市屬專業(yè)機(jī)構(gòu)。研究所現(xiàn)設(shè)細(xì)胞與分子生物學(xué)研究室、流行病學(xué)研究室、血管檢測(cè)中心、社區(qū)高血壓防治中心，以及臨床測(cè)試實(shí)驗(yàn)室、實(shí)驗(yàn)動(dòng)物房等分支機(jī)構(gòu)。
研究所是“醫(yī)學(xué)基因組學(xué)國(guó)家重點(diǎn)實(shí)驗(yàn)室”成員單位，設(shè)有“上海市高血壓重點(diǎn)實(shí)驗(yàn)室”，參與建設(shè)國(guó)家重大科學(xué)設(shè)施“國(guó)家轉(zhuǎn)化醫(yī)學(xué)研究中心”，是教育部國(guó)家重點(diǎn)學(xué)科（心血管內(nèi)科學(xué)）、上海交通大學(xué)醫(yī)學(xué)院心血管內(nèi)科專業(yè)博士和碩士研究生招生單位。目前，研究重點(diǎn)為高血壓相關(guān)基因、血管“重塑”機(jī)制和血管干祖細(xì)胞、流行病學(xué)、血管結(jié)構(gòu)與功能檢測(cè)以及繼發(fā)性高血壓篩查、高血壓靶器官損傷早期檢測(cè)、難治性高血壓治療。
瑞金醫(yī)院高血壓科與研究所實(shí)行所科合一管理體制，本部院區(qū)設(shè)有35張床位，北部院區(qū)設(shè)有25張床位，在兩個(gè)院區(qū)均設(shè)立全日高血壓專科門診，提供急、危、重癥或復(fù)雜高血壓診治服務(wù)。
所長(zhǎng)和科主任為王繼光教授，現(xiàn)任中國(guó)高血壓聯(lián)盟主席、HOPE Asia副主席、前國(guó)際高血壓學(xué)會(huì)執(zhí)委、亞太高血壓學(xué)會(huì)主席、亞洲動(dòng)脈學(xué)會(huì)主席。擔(dān)任Journal of Clinical Hypertension主編、Hypertension副主編、Hypertension Research 副主編、Pulse共同主編、《中華心血管病雜志》副總編等。王繼光教授長(zhǎng)期從事高血壓診治與科研工作，在高血壓人群研究及臨床研究方面取得豐碩成果，獲得華夏醫(yī)學(xué)科技二等獎(jiǎng)。
研究所開展腎素、兒茶酚胺等高血壓專業(yè)特色檢測(cè)服務(wù)，以及動(dòng)態(tài)血壓監(jiān)測(cè)、心臟超聲、頸動(dòng)脈超聲、大動(dòng)脈彈性功能、內(nèi)皮功能、自主神經(jīng)功能、壓力反射敏感性等專業(yè)檢測(cè)服務(wù)。
研究所與澳大利亞、比利時(shí)、加拿大、法國(guó)、日本、英國(guó)、美國(guó)等多個(gè)國(guó)家的科研機(jī)構(gòu)或科學(xué)家建立了良好的合作關(guān)系。聯(lián)合申報(bào)國(guó)際合作科研項(xiàng)目，共同開展高血壓及其并發(fā)癥相關(guān)科學(xué)研究。
Shanghai Institute of Hypertension
The Shanghai Institute of Hypertension was established in the year of 1958 by the municipal government of Shanghai, and is devoted to epidemiological, clinical, pathophysiological, and community studies on hypertension. The Institute is currently composed of Laboratory of Cellular and Molecular Biology, Centre for Epidemiological Studies and Clinical Trials, Centre for Vascular Evaluations, Centre for Hypertension Management and Prevention in Community, Clinical Laboratory, and Laboratory of Experimental Animals.
The Institute is a member of the State Key Laboratory of Medical Genomics and has the Shanghai Key Laboratory of Hypertension. The institute participates in the construction of the national major scientific infrastructure "National Research Centre for Translational Medicine" and belongs to state key discipline (cardiovascular internal medicine) of the Ministry of Education. The Institute also provides educational opportunities for graduate students of doctors and masters in cardiovascular medicine. The current research in the Institute focuses on human genetics in hypertension, vascular remodeling and vascular stem and progenitor cells, clinical trials and epidemiology, vascular structure and function, screening of secondary hypertension, early detection of target organ damage, and treatment of refractory hypertension.
The Department of Hypertension of Ruijin Hospital is the clinical wing of the Institute, with 35 and 25 beds in the main and north campuses, respectively. In both campuses, there is full-time outpatient clinic service for the treatment of hypertension, particularly acute, critical, severe or complicated hypertension.
Professor Ji-Guang Wang is director of the Shanghai Institute of Hypertension and director of the Department of Hypertension. He is the president of the Chinese Hypertension League, deputy president of the HOPE Asia Network, a former executive council member of the International Society of Hypertension, past president of the Asian-Pacific Society of Hypertension, and past president of the Pulse of Asia Society. He serves on the editorial board of several national and international journals in the field of hypertension and cardiovascular disease, such as the Journal of Clinical Hypertension (Editor-in-Chief), Hypertension (Associate Editor), Hypertension Research (Associate Editor), Pulse (Co-Editor), and Chinese Journal of Cardiology (Associate Editor). Professor Wang has published more than 500 articles in the international literature and lectured extensively in international and national scientific conferences. The research work of his team was awarded a second prize of Huaxia Medical Scientific and Technological Awards in 2015.
The Institute also provides service for several clinical and laboratory measurements in relation to hypertension, such as plasma renin activity, urinary catecholamines, ambulatory blood pressure monitoring, echocardiography, carotid ultrasonography, arterial stiffness, endothelial function, autonomous nervous function and baroreflex sensitivity.
The Institute has developed collaborative partnership with scientists and scientific institutions from several countries, such as Australia, Belgium, Canada, France, Japan, UK、and the United States of America.
